Philip Bielefeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Philip Bielefeld has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
J.-F. Besancenot
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
3 shared publications- David Saadoun
Sorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, F-75013, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Centre National de Référence Maladies Autoinflammatoires et Amylose Inflammatoire (CEREMAIA), Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), CIC Biotherapy, INSERM 959, Groupe Hospitalier Pitié-Salpetriere, AP-HP, Paris, France
2 shared publications - Hervé Devilliers
INSERM CIC-1432 Clinical Investigation Center, Clinical Epidemiology, University Hospital of Dijon, France; Internal Medicine and Systemic Diseases unit, University Hospital of Dijon, France
2 shared publications - Sylvain Audia
Department of Internal Medicine, Université Bourgogne Europe, Dijon, France
2 shared publications A. Arbault
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
1 shared publicationA. Muselier
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
1 shared publication
Latest Publications
- 13 February 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 238, 173-180
Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients
- 13 February 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 238, 173-180
Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients
- 1 June 2014
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 35, A40-A41
Intérêt de l’interféron pégylé alpha 2a dans le traitement des uvéites de la maladie de Behçet : à propos de 5 patients
- 1 June 2014
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 35, A40-A41
Intérêt de l’interféron pégylé alpha 2a dans le traitement des uvéites de la maladie de Behçet : à propos de 5 patients
- 1 June 2013
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (Suppl 3) , A909
AB0398 Responsiveness of a generic and disease specific health related quality of life questionnaire in patients with systemic lupus erythematosus.
Background Little is published on comparative responsiveness of generic and disease specific Patients reported outcomes (PRO) tool in systemic lupus erythematosus (SLE). Objectives To determine and compare the responsiveness and minimally clinical important difference (MCID) of a generic and disease specific PRO measure in SLE. Methods SLE patients from a French multicenter study were clinically assessed for activity (SELENA-SLEDAI) at baseline, MOS Short Form 36 (SF-36), LupusQoL, and an overall health status item at baseline (D0), 3 (M3) and 6 (M6) months. Self-reported overall health status item enquired about the impact of lupus on overall health since past visit. Its 7 response options were: -3 “much improved”, -2 “moderately improved”, -1 “minimally improved”, 0 “the same”, +1 “minimally worse”, +2 “moderately worse” and +3 “much worse”. Responsiveness and MCID for SF-36 and LupusQoL domains were determined against +1 or -1 change in overall health status (Anchor-based approach). Descriptives and standardized response mean (SRM) of variations in SF36 and LupusQoL domains were estimated and compared using mixed models methods. Results We included 185 SLE patients. Mean (SD) age and SELENA-SLEDAI were 39.6 (10.6) years and 2.6 (3.5). We analyzed 3 time-point data (515 visits) and two consecutive time-point data (306 visits). LupusQoL “Body Image”, “Fatigue”, and “Burden to others” domains did not change significantly with “worsening” in overall health status; while LupusQoL “body image”, and SF-36 “General Health” and “Physical Functioning” domains did not change significantly with an “improvement” in overall health status. SRM in comparable domains of SF-36 and LupusQoL were similar, except for improvement in LupusQoL Physical Health. SRM ranged from small-moderate for all domains on both measures (table). Conclusions Both SF-36 and LupusQoL show responsiveness in most domains with change in overall health status. LupusQoL is more responsive to improvement, while SF-36 is more responsive to worsening in overall health status. Disclosure of Interest H. Devilliers Consultant for: GlaxoSmithKline, Z. Amoura Consultant for: Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Neovacs, Roche, Teva Pharmaceuticals, and UCB Pharma, S. Audia: None Declared, M. Jolly Consultant for: GSK, Medimmune, P. Bielefeld: None Declared, L. Arnaud Consultant for: Amgen, C. Binquet: None Declared, J.-F. Besancenot: None Declared
- 1 June 2013
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (Suppl 3) , A909
AB0398 Responsiveness of a generic and disease specific health related quality of life questionnaire in patients with systemic lupus erythematosus.
Background Little is published on comparative responsiveness of generic and disease specific Patients reported outcomes (PRO) tool in systemic lupus erythematosus (SLE). Objectives To determine and compare the responsiveness and minimally clinical important difference (MCID) of a generic and disease specific PRO measure in SLE. Methods SLE patients from a French multicenter study were clinically assessed for activity (SELENA-SLEDAI) at baseline, MOS Short Form 36 (SF-36), LupusQoL, and an overall health status item at baseline (D0), 3 (M3) and 6 (M6) months. Self-reported overall health status item enquired about the impact of lupus on overall health since past visit. Its 7 response options were: -3 “much improved”, -2 “moderately improved”, -1 “minimally improved”, 0 “the same”, +1 “minimally worse”, +2 “moderately worse” and +3 “much worse”. Responsiveness and MCID for SF-36 and LupusQoL domains were determined against +1 or -1 change in overall health status (Anchor-based approach). Descriptives and standardized response mean (SRM) of variations in SF36 and LupusQoL domains were estimated and compared using mixed models methods. Results We included 185 SLE patients. Mean (SD) age and SELENA-SLEDAI were 39.6 (10.6) years and 2.6 (3.5). We analyzed 3 time-point data (515 visits) and two consecutive time-point data (306 visits). LupusQoL “Body Image”, “Fatigue”, and “Burden to others” domains did not change significantly with “worsening” in overall health status; while LupusQoL “body image”, and SF-36 “General Health” and “Physical Functioning” domains did not change significantly with an “improvement” in overall health status. SRM in comparable domains of SF-36 and LupusQoL were similar, except for improvement in LupusQoL Physical Health. SRM ranged from small-moderate for all domains on both measures (table). Conclusions Both SF-36 and LupusQoL show responsiveness in most domains with change in overall health status. LupusQoL is more responsive to improvement, while SF-36 is more responsive to worsening in overall health status. Disclosure of Interest H. Devilliers Consultant for: GlaxoSmithKline, Z. Amoura Consultant for: Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Neovacs, Roche, Teva Pharmaceuticals, and UCB Pharma, S. Audia: None Declared, M. Jolly Consultant for: GSK, Medimmune, P. Bielefeld: None Declared, L. Arnaud Consultant for: Amgen, C. Binquet: None Declared, J.-F. Besancenot: None Declared
- 1 December 2011
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 32, S418-S419
Étude fonctionnelle et phénotypique des cellules dendritiques humaines et des lymphocytes T au cours de la sclérodermie systémique
- 1 December 2011
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 32, S418-S419
Étude fonctionnelle et phénotypique des cellules dendritiques humaines et des lymphocytes T au cours de la sclérodermie systémique